The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.

The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

SEATTLE – Guidelines for germline genetic testing have changed rapidly in recent years, and community cancer centers are struggling to implement programs that can identify and facilitate testing for ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.

The agency reviewed data from a Phase II study, in which around 21 percent of patients had a complete response to the menin inhibitor.

NEW YORK – German biotech ITM Isotope Technologies Munich has submitted a new drug application to the US Food and Drug Administration for its radiopharmaceutical 177Lu-edotreotide as a treatment for ...

NEW YORK – The American College of Medical Genetics and Genomics (ACMG) this week released a clinical practice resource for the management of patients with heterozygous germline pathogenic variants in ...